Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: Matuzumab, Merck KGaA.

Tracy Kim1

  • 1tracy.e.kim@kp.org

Current Opinion in Molecular Therapeutics
|March 12, 2004
PubMed
Summary

Merck KGaA is investigating matuzumab, an epidermal growth factor receptor (EGFR)-targeting antibody, for various cancers. This therapy is currently in phase II clinical trials for gastric, cervical, pancreatic, and ovarian tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling patient-related workload in the emergency department using electronic health record data.

International journal of medical informatics·2021
Same author

Were domestic camelids present on the prehispanic South American agricultural frontier? An ancient DNA study.

PloS one·2020
Same author

Objective measures of workload in healthcare: a narrative review.

International journal of health care quality assurance·2020
Same author

Understanding the perception of workload in the emergency department and its impact on medical decision making.

The American journal of emergency medicine·2019
Same author

Diagnosis of Hypofibrinogenemia After Dental Treatment Under General Anesthesia.

Pediatric dentistry·2018

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Epidermal Growth Factor Receptor (EGFR) is frequently overexpressed in various solid tumors.
  • Targeting EGFR offers a potential therapeutic strategy for cancer treatment.
  • Monoclonal antibodies provide targeted delivery of therapeutic payloads or blockade of receptor function.

Purpose of the Study:

  • To evaluate the safety and efficacy of matuzumab, a fully humanized monoclonal antibody, in patients with EGFR-expressing tumors.
  • To assess the potential of matuzumab as a treatment for advanced or metastatic cancers.

Main Methods:

  • Matuzumab is a fully humanized monoclonal antibody that specifically binds to the epidermal growth factor receptor (EGFR).
  • The drug is currently being investigated in phase II clinical trials.
  • Patient populations include those with gastric, cervical, pancreatic, and ovarian cancers.

Main Results:

  • Phase II clinical trials are ongoing, therefore, definitive results are not yet available.
  • The study aims to determine the objective response rate and progression-free survival in patients treated with matuzumab.
  • Biomarker analysis will likely assess EGFR expression levels and their correlation with treatment response.

Conclusions:

  • Matuzumab represents a promising targeted therapy candidate for EGFR-driven malignancies.
  • Ongoing clinical trials will elucidate the therapeutic role of matuzumab in specific cancer types.
  • Further research may explore combination therapies to enhance treatment outcomes.

Related Experiment Videos